Drug Type Small molecule drug |
Synonyms Brivaracetam (JAN/USAN/INN), BRIVIACT CV, BRIVLERA + [10] |
Target |
Action modulators |
Mechanism SV2A modulators(Synaptic vesicle glycoprotein 2A modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (13 Jan 2016), |
RegulationOrphan Drug (United States) |
Molecular FormulaC11H20N2O2 |
InChIKeyMSYKRHVOOPPJKU-BDAKNGLRSA-N |
CAS Registry357336-20-0 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D08879 | Brivaracetam |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Epilepsy | United States | 18 Feb 2016 | |
| Epilepsies, Partial | European Union | 13 Jan 2016 | |
| Epilepsies, Partial | Iceland | 13 Jan 2016 | |
| Epilepsies, Partial | Liechtenstein | 13 Jan 2016 | |
| Epilepsies, Partial | Norway | 13 Jan 2016 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Epilepsy, Absence | Phase 3 | United States | 29 Jul 2021 | |
| Epilepsy, Absence | Phase 3 | Italy | 29 Jul 2021 | |
| Epilepsy, Absence | Phase 3 | Romania | 29 Jul 2021 | |
| Epilepsy, Absence | Phase 3 | Slovakia | 29 Jul 2021 | |
| Epilepsy, Absence | Phase 3 | Spain | 29 Jul 2021 | |
| Epilepsy, Absence | Phase 3 | Ukraine | 29 Jul 2021 | |
| Epilepsy, Benign Neonatal | Phase 3 | Belgium | 07 May 2019 | |
| Epilepsy, Benign Neonatal | Phase 3 | Czechia | 07 May 2019 | |
| Epilepsy, Benign Neonatal | Phase 3 | France | 07 May 2019 | |
| Epilepsy, Benign Neonatal | Phase 3 | Germany | 07 May 2019 |
Phase 3 | 44 | (Experimental Group) | qozwszpjan(njbbhwufpv) = xkxhynwsim vvpbyvskfq (zmmiyxnbvw, 2.0) View more | - | 18 Mar 2026 | ||
Placebo (Control Group) | qozwszpjan(njbbhwufpv) = mqqsvjhhah vvpbyvskfq (zmmiyxnbvw, 1.5) View more | ||||||
Phase 3 | 448 | Placebo | zwqxocbrws(ndbgnrcudk) = yuyfbcwysn eoqghrfxiv (gyqinfnayv ) View more | Positive | 01 Nov 2025 | ||
zwqxocbrws(ycmgymrggp) = pogxhpxejd qgpfdqabbe (haflemmilo ) View more | |||||||
Phase 3 | 84 | (Childhood Absence Epilepsy (CAE): Brivaracetam) | lvztifvtlm = tekynbdtgo atperzpluv (sowzrlbhma, infhgtsofp - wjsgoujwcu) View more | - | 07 Oct 2025 | ||
(Juvenile Absence Epilepsy (JAE): Brivaracetam) | lvztifvtlm = qbekhdnien atperzpluv (sowzrlbhma, oaiwgxadui - gziiawullf) View more | ||||||
Phase 3 | 101 | (Generalized-onset seizures) | sumitojqnl(hxbxbmbybn) = Mean changes from baseline to last evaluation in Achenbach CBCL 1.5-5 raw syndrome scores (n = 18) were all around 0 (minimal/small amplitude). Mean changes in CBCL 6-18 raw syndrome scores (n = 20) showed small numerical improvements for most syndromes. At last evaluation, most patients (range: 61.1 %-100 %) remained in baseline T-score categories. xmxodhaqge (ykqiykvbzm ) View more | Positive | 01 Oct 2025 | ||
Not Applicable | 103 | thywtpamdg(qhurwlojqw) = ihvllgdfbc mygqcvisru (isksfzxnox ) View more | Positive | 30 Aug 2025 | |||
(switched from Levetiracetam) | uoyspdrwes(gsiskwhvxj) = nlplhxjpwi dcsajsitbc (zodogfzzhu ) | ||||||
Not Applicable | 798 | lpbczlfimo(qtlvmufppy) = 75.6% of physicians reported any improvement (minimally/much/very much) in their patients, 20.4% no change, 4.0% any worsening (minimally/much/very much). xoipsyjbot (igzunfqfhm ) | Positive | 30 Aug 2025 | |||
(Pediatric Patients) | |||||||
Phase 3 | 207 | (EP0083 Placebo) | nbbndyxkuq = qvvizlstwz kfoiozlrsd (nwyfklmqox, fhgrufkxtw - chgtjhppsi) View more | - | 29 Jul 2025 | ||
BRV (EP0083 BRV All) | nbbndyxkuq = eqsoykbxwy kfoiozlrsd (nwyfklmqox, axcmmztfxo - msazgaiaiu) View more | ||||||
Phase 3 | 207 | zyqesirspf(ugbwtghgku) = jvhzovzpqi uedbhcrrdq (jjmxprkkif ) View more | Positive | 23 Jun 2025 | |||
Placebo | zlsscgdxsd(yvahodsied) = gzitmuedgj kkbvjcbupf (hwduwowban ) | ||||||
Phase 1 | - | 64 | BRV (BRV Tablet) | ejfcltdkri(hgujmeczkt) = zquazpflhy booatgzxfb (oizanoobok, 24.1) View more | - | 06 Jun 2025 | |
BRV (BRV Dry Syrup) | ejfcltdkri(hgujmeczkt) = eitfapqhrm booatgzxfb (oizanoobok, 19.5) View more | ||||||
Phase 1/2 | 24 | Placebo (Control Group) | dqgeodnhgm(tobaycmoaj) = opjqxxdfcz qvixzsdchu (pnvdvxiycc, 1) View more | - | 27 Apr 2025 | ||
(Brivaracetam Group) | dqgeodnhgm(tobaycmoaj) = cxdftybgay qvixzsdchu (pnvdvxiycc, 0.8) View more |





